Diversified Trust Co Purchases 7,520 Shares of Repligen Co. (NASDAQ:RGEN)

Diversified Trust Co boosted its position in Repligen Co. (NASDAQ:RGEN) by 255.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,469 shares of the biotechnology company’s stock after purchasing an additional 7,520 shares during the quarter. Diversified Trust Co’s holdings in Repligen were worth $1,558,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Norden Group LLC boosted its position in shares of Repligen by 1,711.6% in the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after purchasing an additional 36,663 shares in the last quarter. Artemis Investment Management LLP boosted its holdings in Repligen by 33.8% in the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after acquiring an additional 42,380 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after acquiring an additional 6,705 shares during the last quarter. Congress Asset Management Co. MA grew its stake in shares of Repligen by 14.6% in the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after acquiring an additional 11,213 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Repligen by 21.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock valued at $61,767,000 after acquiring an additional 59,903 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $135.02 on Wednesday. The stock has a 50-day simple moving average of $149.19 and a two-hundred day simple moving average of $150.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The firm has a market capitalization of $7.54 billion, a PE ratio of 540.08, a P/E/G ratio of 4.24 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. UBS Group decreased their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Wells Fargo & Company began coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and cut their target price for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Finally, Guggenheim started coverage on Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.